Abelacimab Versus Rivaroxaban in Older Adults With Atrial Fibrillation
01 Mar 20264 min read0 viewsJournal Feed
GIST (Key Takeaways)
This randomized clinical trial examines data via prespecified analysis to evaluate the bleeding risk of the novel factor XI inhibitor abelacimab vs rivaroxaban in patients with atrial fibrillation (AF) according to their age (<75 vs ≥75 years).
Clinical Editorial
JAMA Cardiology published a clinical update in Cardiology on 01 Mar 2026.
The item focuses on Abelacimab vs Rivaroxaban in Older Individuals With AF.
Review the original article for the full source wording and details.
Source Reference
Read the full original publication from the source journal or publisher link below.